WO2003057236A1 - Inhibiteur de prise de poids corporel - Google Patents

Inhibiteur de prise de poids corporel Download PDF

Info

Publication number
WO2003057236A1
WO2003057236A1 PCT/JP2002/013781 JP0213781W WO03057236A1 WO 2003057236 A1 WO2003057236 A1 WO 2003057236A1 JP 0213781 W JP0213781 W JP 0213781W WO 03057236 A1 WO03057236 A1 WO 03057236A1
Authority
WO
WIPO (PCT)
Prior art keywords
body weight
weight gain
gain inhibitor
inhibitor
excellent body
Prior art date
Application number
PCT/JP2002/013781
Other languages
English (en)
French (fr)
Inventor
Hirokazu Matsumoto
Jiro Noguchi
Mioko Harada
Masaaki Mori
Original Assignee
Takeda Chemical Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries, Ltd. filed Critical Takeda Chemical Industries, Ltd.
Priority to CA002471768A priority Critical patent/CA2471768A1/en
Priority to AU2002362165A priority patent/AU2002362165A1/en
Priority to US10/500,175 priority patent/US7375074B2/en
Priority to EP02796974A priority patent/EP1459755A4/en
Publication of WO2003057236A1 publication Critical patent/WO2003057236A1/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PCT/JP2002/013781 2001-12-28 2002-12-27 Inhibiteur de prise de poids corporel WO2003057236A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002471768A CA2471768A1 (en) 2001-12-28 2002-12-27 Body weight gain inhibitor
AU2002362165A AU2002362165A1 (en) 2001-12-28 2002-12-27 Body weight gain inhibitor
US10/500,175 US7375074B2 (en) 2001-12-28 2002-12-27 Body weight gain inhibitor
EP02796974A EP1459755A4 (en) 2001-12-28 2002-12-27 BODY WEIGHT TAKING INHIBITOR

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001403260 2001-12-28
JP2001-403260 2001-12-28
JP2002-93096 2002-03-28
JP2002093096 2002-03-28

Publications (1)

Publication Number Publication Date
WO2003057236A1 true WO2003057236A1 (fr) 2003-07-17

Family

ID=26625427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/013781 WO2003057236A1 (fr) 2001-12-28 2002-12-27 Inhibiteur de prise de poids corporel

Country Status (5)

Country Link
US (1) US7375074B2 (ja)
EP (1) EP1459755A4 (ja)
AU (1) AU2002362165A1 (ja)
CA (1) CA2471768A1 (ja)
WO (1) WO2003057236A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268212B2 (en) 2001-06-14 2007-09-11 Takeda Pharmaceutical Company Limited Ligand of G protein-coupled receptor protein and DNA thereof
US7763716B2 (en) 2003-05-28 2010-07-27 Takeda Pharmaceutical Company Limited Antibody against NPW

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008073578A2 (en) 2006-12-08 2008-06-19 Iowa State University Research Foundation, Inc. Plant genes involved in nitrate uptake and metabolism

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012670A1 (en) * 1993-11-05 1995-05-11 Alcoholism And Drug Addiction Research Foundation Opioid receptor: compositions and methods
JPH09121865A (ja) * 1995-10-30 1997-05-13 Takeda Chem Ind Ltd 新規ｇ蛋白質共役型レセプター蛋白質、その製造法および用途
WO2001098494A1 (fr) * 2000-06-21 2001-12-27 Takeda Chemical Industries, Ltd Ligand de gpr8 et son adn

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344823A4 (en) * 2000-11-30 2005-03-16 Takeda Chemical Industries Ltd NEW G-PROTEIN-COUPLED RECEPTOR PROTEINS AND THEIR DNAS
EP1403281B1 (en) * 2001-06-14 2008-07-09 Takeda Pharmaceutical Company Limited Novel ligand and dna thereof
AU2003221533A1 (en) * 2002-03-29 2003-10-13 Euroscreen Sa Ligands for g protein coupled receptor gpr7 and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012670A1 (en) * 1993-11-05 1995-05-11 Alcoholism And Drug Addiction Research Foundation Opioid receptor: compositions and methods
JPH09121865A (ja) * 1995-10-30 1997-05-13 Takeda Chem Ind Ltd 新規ｇ蛋白質共役型レセプター蛋白質、その製造法および用途
WO2001098494A1 (fr) * 2000-06-21 2001-12-27 Takeda Chemical Industries, Ltd Ligand de gpr8 et son adn

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
O'DOWD B.F. ET AL.: "The cloning and chromosomal mapping of two novel human opioid-somatostatin-like receptor genes, GPR7 and GPR8, expressed in discrete areas of the brain", GENOMICS, vol. 28, no. 1, 1995, pages 84 - 91, XP002967040 *
See also references of EP1459755A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268212B2 (en) 2001-06-14 2007-09-11 Takeda Pharmaceutical Company Limited Ligand of G protein-coupled receptor protein and DNA thereof
US7763716B2 (en) 2003-05-28 2010-07-27 Takeda Pharmaceutical Company Limited Antibody against NPW

Also Published As

Publication number Publication date
US7375074B2 (en) 2008-05-20
CA2471768A1 (en) 2003-07-17
EP1459755A1 (en) 2004-09-22
US20050124539A1 (en) 2005-06-09
AU2002362165A1 (en) 2003-07-24
EP1459755A4 (en) 2007-10-31

Similar Documents

Publication Publication Date Title
AU2003265228A1 (en) Assay device that analyzes the absorption, metabolism, permeability and/or toxicity of a candidate compound
WO2004079937A3 (en) An ultra-wideband transceiver architecture and associated methods
WO2002074748A8 (en) Metalloproteinase inhibitors
WO2003035617A3 (en) Derivatives of uk-2a
MXPA03008850A (es) Inhibidores de aldosa reductasa del grupo de las piridazinonas.
WO2004052783A3 (en) Soluble carbon nanotubes
AU2002350140A1 (en) Noncoherent integration, gain enhancement technique for non-stationary targets
AU2003281287A1 (en) Toxicity markers
AU2003281983A1 (en) Amplifier assembly
WO2003078574A3 (en) Novel metabolic targets and markers
AU2003277721A1 (en) Beta-nitrostyrene compound and telomerase inhibitor having an anticancer activity
AU2002364386A1 (en) Amplitude peak cancellation
MXPA03009002A (es) 5-halogeno-6-fenil-7-fluoroalquilamino-triazolopirimidinas.
AU2002342094A1 (en) Adaptive transmitter power amplifier
EP1671948A4 (en) CINNAMOYL COMPOUND AND USE THEREOF
WO2002080855A3 (en) Methods and compounds for decreasing cell toxicity or death
EP1671961A4 (en) CINNAMOYL COMPOUND AND USE THEREOF
WO2003057236A1 (fr) Inhibiteur de prise de poids corporel
EP1403963A3 (en) AM Antenna Noise Reduction
GB2393052A8 (en) Control of the bias in an amplifier or mixer of a receiver for improved dynamic range, noise performance and efficiency
AU2002306488A1 (en) Photochemical amplified immunoassay
AU2003271959A1 (en) Amplifier assembly
AU2003230738A1 (en) Active-loop, spatially-combined amplifier
WO2001055198A3 (de) Haut- und magen-spezifischer sphingolipid-aktivator
AU2002350963A1 (en) Low noise synthesiser

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002796974

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10500175

Country of ref document: US

Ref document number: 2471768

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002796974

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP